FY2030 EPS Estimate for IceCure Medical Decreased by Analyst

IceCure Medical Ltd. (NASDAQ:ICCM) – Research analysts at Brookline Capital Markets reduced their FY2030 earnings per share estimates for IceCure Medical in a report issued on Wednesday, August 12th. Brookline Capital Markets analyst K. Dolliver now expects that the company will earn $2.98 per share for the year, down from their prior forecast of $3.21. The consensus estimate for IceCure Medical’s current full-year earnings is ($3.51) per share.

ICCM has been the topic of several other research reports. Wall Street Zen raised IceCure Medical to a “sell” rating in a report on Sunday, July 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of IceCure Medical in a research report on Friday, July 17th. Maxim Group cut their price target on IceCure Medical from $90.00 to $30.00 and set a “buy” rating on the stock in a research report on Thursday, May 14th. Finally, Alliance Global Partners began coverage on IceCure Medical in a report on Monday, May 4th. They issued a “buy” rating for the company. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, IceCure Medical currently has a consensus rating of “Hold” and an average target price of $52.50.

IceCure Medical Price Performance

Shares of ICCM opened at $3.00 on Friday. IceCure Medical has a 1-year low of $2.12 and a 1-year high of $42.00. The stock has a market cap of $10.29 million, a PE ratio of -0.35 and a beta of 0.47. The firm has a fifty day moving average price of $3.95 and a 200 day moving average price of $9.83.

IceCure Medical (NASDAQ:ICCM) last issued its quarterly earnings data on Tuesday, June 30th. The company reported ($1.64) earnings per share for the quarter. The company had revenue of $0.91 million for the quarter. IceCure Medical had a negative return on equity of 188.60% and a negative net margin of 427.67%.

Hedge Funds Weigh In On IceCure Medical

A number of large investors have recently modified their holdings of ICCM. Virtu Financial LLC acquired a new stake in shares of IceCure Medical in the 4th quarter valued at approximately $39,000. Jane Street Group LLC acquired a new position in IceCure Medical during the fourth quarter worth $67,000. Finally, Concurrent Investment Advisors LLC acquired a new position in IceCure Medical during the fourth quarter worth $48,000. 0.62% of the stock is owned by hedge funds and other institutional investors.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.